Moderna (MRNA) Total Non-Current Liabilities (2017 - 2026)

Moderna (MRNA) has 10 years of Total Non-Current Liabilities data on file, last reported at $3.8 billion in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $3.8 billion, up 60.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 billion (up 60.62% YoY), and the FY2025 annual result was $3.4 billion, up 14.43% from the prior year.
• Total Non-Current Liabilities climbed to $3.8 billion in Q1 2026 per MRNA's latest filing, from $3.4 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $10.4 billion in Q1 2022 and troughed at $2.3 billion in Q2 2025.
• A 5-year average of $4.8 billion and a median of $3.8 billion in 2026 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities plunged 51.17% in 2023, then surged 60.62% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $6.6 billion in 2022, then slumped by 34.61% to $4.3 billion in 2023, then plunged by 31.09% to $3.0 billion in 2024, then advanced by 14.43% to $3.4 billion in 2025, then gained by 11.58% to $3.8 billion in 2026.
• Business Quant data shows MRNA's Total Non-Current Liabilities at $3.8 billion in Q1 2026, $3.4 billion in Q4 2025, and $2.5 billion in Q3 2025.